{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-116736","form_type":"8-K","ticker":"AVBP","cik":"0001868279","company_name":"ArriVent BioPharma, Inc.","filed_at":"2026-10-19T12:08:31+00:00","discovered_at":"2026-10-19T12:10:00.369909+00:00","generated_at":"2026-10-19T12:10:04.940101+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ArriVent firmonertinib FURTHER Phase 1b data published in Cancer Cell: ORR 43-68% in EGFR PACC NSCLC","bullets":["Confirmed ORR 43% at 160 mg and 68% at 240 mg, with median PFS of 11.1 and 16.0 months by BICR in front-line EGFR PACC-mutant NSCLC.","Intracranial ORR of 47% (8/17), including 41% complete responses, among 17 patients with baseline brain metastases.","80% of evaluable patients achieved complete ctDNA molecular response by cycle 3; those patients showed ORR 70% vs 20% and PFS 15.1 vs 3.0 months.","EGFR PACC mutations are ~12% of EGFR-mutant tumors with no established targeted standard of care; firmonertinib showed enhanced in vitro potency vs osimertinib.","Global Phase 3 ALPACCA trial (FURMO-006; NCT07185997) is enrolling, testing firmonertinib vs investigator's choice of osimertinib or afatinib in first-line disease."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-116736","json":"https://secwatch.observer/filing/0001104659-26-116736.json","markdown":"https://secwatch.observer/filing/0001104659-26-116736.md","text":"https://secwatch.observer/filing/0001104659-26-116736.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1868279/000110465926116736/0001104659-26-116736-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1868279/000110465926116736/tm2627799d1_8k.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-19T12:10:04.940101+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}